Reported covered position: Acting General Counsel, Dept. of Health and Human Services
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2026 · third_quarter · Q3
Policies related to Medicare reimbursement for cancer diagnostics.
Improved patient access to cancer screening diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Source: Senate LDA
2026 · second_quarter · Q2
Policies related to Medicare reimbursement for cancer diagnostics.
Improved patient access to cancer screening diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2026 · first_quarter · Q1
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · fourth_quarter · Q4
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · third_quarter · Q3
Improved patient access to cancer screening diagnostics.
Policies related to Medicare reimbursement for cancer diagnostics.
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
PRELUDE CORPORATION (PRELUDEDX) via DLA PIPER LLP (US)
2025 · third_quarter · RR
Policies regarding Medicare reimbursement for cancer diagnostic.
Policies regarding Medicare reimbursement for cancer diagnostic.